Assembly Biosciences reports promising interim results for HBV core inhibitors 3733 and 4334

ASSEMBLY BIOSCIENCES, INC.

ABI-H3733 50 mg cohort: 6 of 8 HBV patients reached HBV DNA <LLOQ by day 21; mean 3.1 log decline.
No serious adverse events or significant ALT elevations observed in either study.
ABI-4334 30 mg single-dose showed 24-hour half-life supporting once-daily oral dosing; PK suggests high potency.
100 mg cohorts ongoing for both studies; further data expected in Q1 2023.
ABI-H3733 25 mg cohort enrolled; initial 5 patients showed mean HBV DNA reduction of ~1.9 logs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.